AstraZeneca finds early-stage success with MET inhibitor in lung cancer - BioPharma Dive

AstraZeneca finds early-stage success with MET inhibitor in lung cancer  BioPharma Dive

AstraZeneca and Chi-Med's investigational MET inhibitor gave lung cancer patients additional benefit when used in combination with the British pharma's EFGR ...



Comments

Popular posts from this blog

Stage 4 Lung Cancer Life Expectancy

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Free biotech stocks directory, pharma stocks, telemedicine stocks ...